Oppenheimer Maintains Outperform on Seres Therapeutics, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones has maintained an Outperform rating on Seres Therapeutics (NASDAQ:MCRB) but has lowered the price target from $9 to $5.

March 06, 2024 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oppenheimer maintains an Outperform rating on Seres Therapeutics but lowers the price target from $9 to $5.
While the maintenance of an Outperform rating suggests continued confidence in the company's long-term prospects, the reduction in the price target could indicate near-term challenges or a recalibration of expectations, potentially leading to mixed short-term market reactions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100